Urogen Pharma Ltd (URGN) has a current Price-to-Book (P/B) ratio of -9.21. Compared to its 3-year average P/B ratio of -3.69, the current P/B ratio is approximately 149.71% higher. Relative to its 5-year average P/B ratio of -0.83, the current P/B ratio is about 1013.40% higher. Urogen Pharma Ltd (URGN) has a Forward Free Cash Flow (FCF) yield of approximately -12.99%. Compared to its 3-year average FCF yield of -20.57%, the current FCF yield is approximately -36.83% lower. Relative to its 5-year average FCF yield of -28.00%, the current FCF yield is about -53.60% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for URGN competitors is 9.32, providing a benchmark for relative valuation. Urogen Pharma Ltd Corp (URGN.O) exhibits a P/S ratio of 5.26, which is -43.63% above the industry average. Given its robust revenue growth of 9.04%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of URGN increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of URGN in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is URGN currently overvalued or undervalued?

What is Urogen Pharma Ltd (URGN) fair value?

URGN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Urogen Pharma Ltd (URGN) is between 15.68 to 24.79 according to relative valuation method.

How does URGN's valuation metrics compare to the industry average?

The average P/S ratio for URGN's competitors is 9.32, providing a benchmark for relative valuation. Urogen Pharma Ltd Corp (URGN) exhibits a P/S ratio of 5.26, which is -43.63% above the industry average. Given its robust revenue growth of 9.04%, this premium appears unsustainable.

What is the current P/B ratio for Urogen Pharma Ltd (URGN) as of Mar 02 2026?

As of Mar 02 2026, Urogen Pharma Ltd (URGN) has a P/B ratio of -9.21. This indicates that the market values URGN at -9.21 times its book value.

What is the current FCF Yield for Urogen Pharma Ltd (URGN) as of Mar 02 2026?

As of Mar 02 2026, Urogen Pharma Ltd (URGN) has a FCF Yield of -12.99%. This means that for every dollar of Urogen Pharma Ltd's market capitalization, the company generates -12.99 cents in free cash flow.

What is the current Forward P/E ratio for Urogen Pharma Ltd (URGN) as of Mar 02 2026?

As of Mar 02 2026, Urogen Pharma Ltd (URGN) has a Forward P/E ratio of -14.68. This means the market is willing to pay $-14.68 for every dollar of Urogen Pharma Ltd's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Urogen Pharma Ltd (URGN) as of Mar 02 2026?

As of Mar 02 2026, Urogen Pharma Ltd (URGN) has a Forward P/S ratio of 5.26. This means the market is valuing URGN at $5.26 for every dollar of expected revenue over the next 12 months.

URGN Valuation